{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:46:00Z","timestamp":1794980760342,"version":"4.9.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HD100365"],"award-info":[{"award-number":["R01HD100365"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Howard W. and Georgeanna Seegar Jones Endowment","id":[{"id":"https:\/\/ror.org\/0229evh14","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Fibrosis is characterized by excessive accumulation of extracellular matrix, which is a key feature of uterine fibroids. Our prior research supports the tenet that inhibition of fibrotic processes may restrict fibroid growth. Epigallocatechin gallate (EGCG), a green tea compound with powerful antioxidant properties, is an investigational drug for uterine fibroids. An early phase clinical trial showed that EGCG was effective in reducing fibroid size and its associated symptoms; however, its mechanism of action(s) has not been completely elucidated. Here, we probed effects of EGCG on key signaling pathways involved in fibroid cell fibrosis. Viability of myometrial and fibroid cells was not greatly affected by EGCG treatment (1\u2013200\u00a0\u00b5M). Cyclin D1, a protein involved in cell cycle progression, was increased in fibroid cells and was significantly reduced by EGCG. EGCG treatment significantly reduced mRNA or protein levels of key fibrotic proteins, including fibronectin (\n                    <jats:italic>FN1<\/jats:italic>\n                    ), collagen (\n                    <jats:italic>COL1A1<\/jats:italic>\n                    ), plasminogen activator inhibitor-1\u00a0(\n                    <jats:italic>PAI-1<\/jats:italic>\n                    ), connective tissue growth factor\u00a0(\n                    <jats:italic>CTGF<\/jats:italic>\n                    ), and actin alpha 2, smooth muscle (\n                    <jats:italic>ACTA2<\/jats:italic>\n                    ) in fibroid cells, suggesting antifibrotic effects. EGCG treatment altered the activation of YAP, \u03b2-catenin, JNK and AKT, but not Smad 2\/3 signaling pathways involved in mediating fibrotic process. Finally, we conducted a comparative study to evaluate the ability of EGCG to regulate fibrosis with synthetic inhibitors. We observed that EGCG displayed greater efficacy than ICG-001 (\u03b2-catenin), SP600125 (JNK) and MK-2206 (AKT)\u00a0inhibitors, and its effects were equivalent to verteporfin (YAP) or SB525334 (Smad) for regulating expression of key fibrotic mediators. These data indicate that EGCG exhibits anti-fibrotic effects in fibroid cells. These results provide insight into mechanisms behind the observed clinical efficacy of EGCG against uterine fibroids.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-35212-6","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T08:02:01Z","timestamp":1685001721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Targeting fibrotic signaling pathways by EGCG as a therapeutic strategy for uterine fibroids"],"prefix":"10.1038","volume":"13","author":[{"given":"Md Soriful","family":"Islam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maclaine","family":"Parish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana L.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Segars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"35212_CR1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1067\/mob.2003.99","volume":"188","author":"D Day Baird","year":"2003","unstructured":"Day Baird, D., Dunson, D. B., Hill, M. C., Cousins, D. & Schectman, J. M. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am. J. Obstet. Gynecol. 188, 100\u2013107 (2003).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"35212_CR2","doi-asserted-by":"publisher","first-page":"1045783","DOI":"10.3389\/fphar.2022.1045783","volume":"13","author":"N Sefah","year":"2023","unstructured":"Sefah, N. et al. Uterine fibroids: Causes, impact, treatment, and lens to the African perspective. Front. Pharmacol. 13, 1045783 (2023).","journal-title":"Front. Pharmacol."},{"key":"35212_CR3","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1210\/endrev\/bnab039","volume":"43","author":"Q Yang","year":"2022","unstructured":"Yang, Q. et al. Comprehensive review of uterine fibroids: Developmental origin, pathogenesis, and treatment. Endocr. Rev. 43, 678\u2013719 (2022).","journal-title":"Endocr. Rev."},{"key":"35212_CR4","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1210\/jc.2012-3237","volume":"98","author":"MS Islam","year":"2013","unstructured":"Islam, M. S. et al. Uterine leiomyoma: Available medical treatments and new possible therapeutic options. J. Clin. Endocrinol. Metab. 98, 921\u2013934 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"35212_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.fertnstert.2014.10.038","volume":"103","author":"J Donnez","year":"2015","unstructured":"Donnez, J. et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil. Steril. 103, 519-527e513 (2015).","journal-title":"Fertil. Steril."},{"key":"35212_CR6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.fertnstert.2018.06.044","volume":"110","author":"J Donnez","year":"2018","unstructured":"Donnez, J. Liver injury and ulipristal acetate: An overstated tragedy?. Fertil. Steril. 110, 593\u2013595 (2018).","journal-title":"Fertil. Steril."},{"key":"35212_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1904351","author":"WD Schlaff","year":"2020","unstructured":"Schlaff, W. D. et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/nejmoa1904351 (2020).","journal-title":"N. Engl. J. Med."},{"key":"35212_CR8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1056\/NEJMoa2008283","volume":"384","author":"A Al-Hendy","year":"2021","unstructured":"Al-Hendy, A. et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. N. Engl. J. Med. 384, 630\u2013642 (2021).","journal-title":"N. Engl. J. Med."},{"key":"35212_CR9","doi-asserted-by":"publisher","first-page":"211.e211","DOI":"10.1016\/j.ajog.2011.12.002","volume":"206","author":"ER Cardozo","year":"2012","unstructured":"Cardozo, E. R. et al. The estimated annual cost of uterine leiomyomata in the United States. Am. J. Obstet. Gynecol. 206, 211.e211-211.e219 (2012).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"35212_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/humupd\/dmx032","volume":"24","author":"MS Islam","year":"2018","unstructured":"Islam, M. S., Ciavattini, A., Petraglia, F., Castellucci, M. & Ciarmela, P. Extracellular matrix in uterine leiomyoma pathogenesis: A potential target for future therapeutics. Hum. Reprod. Update 24, 59\u201385 (2018).","journal-title":"Hum. Reprod. Update"},{"key":"35212_CR11","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1080\/10408398.2016.1245649","volume":"57","author":"MS Islam","year":"2017","unstructured":"Islam, M. S., Akhtar, M. M., Segars, J. H., Castellucci, M. & Ciarmela, P. Molecular targets of dietary phytochemicals for possible prevention and therapy of uterine fibroids: Focus on fibrosis. Crit. Rev. Food Sci. Nutr. 57, 3583\u20133600 (2017).","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"35212_CR12","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/humupd\/dmr031","volume":"17","author":"P Ciarmela","year":"2011","unstructured":"Ciarmela, P. et al. Growth factors and myometrium: Biological effects in uterine fibroid and possible clinical implications. Hum. Reprod. Update 17, 772\u2013790 (2011).","journal-title":"Hum. Reprod. Update"},{"key":"35212_CR13","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1177\/1933719109343310","volume":"16","author":"JM Norian","year":"2009","unstructured":"Norian, J. M. et al. Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. Reprod. Sci. 16, 1153\u20131164 (2009).","journal-title":"Reprod. Sci."},{"key":"35212_CR14","doi-asserted-by":"publisher","first-page":"E775","DOI":"10.1210\/jc.2013-2623","volume":"99","author":"MS Islam","year":"2014","unstructured":"Islam, M. S. et al. Role of activin-A and myostatin and their signaling pathway in human myometrial and leiomyoma cell function. J. Clin. Endocrinol. Metab. 99, E775\u2013E785 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"35212_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.bbrc.2018.08.171","volume":"504","author":"H Bao","year":"2018","unstructured":"Bao, H., Sin, T. K. & Zhang, G. Activin A induces leiomyoma cell proliferation, extracellular matrix (ECM) accumulation and myofibroblastic transformation of myometrial cells via p38 MAPK. Biochem. Biophys. Res. Commun. 504, 447\u2013453 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"35212_CR16","first-page":"59","volume":"2","author":"B Piersma","year":"2015","unstructured":"Piersma, B., Bank, R. A. & Boersema, M. Signaling in fibrosis: TGF-\u03b2, WNT, and YAP\/TAZ converge. Front. Med. (Lausanne) 2, 59 (2015).","journal-title":"Front. Med. (Lausanne)"},{"key":"35212_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1165\/rcmb.2003-0063OC","volume":"29","author":"B Hu","year":"2003","unstructured":"Hu, B., Wu, Z. & Phan, S. H. Smad3 mediates transforming growth factor-\u03b2\u2013induced \u03b1-smooth muscle actin expression. Am. J. Respir. Cell Mol. Biol. 29, 397\u2013404 (2003).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"35212_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3181\/0707-MR-190","volume":"233","author":"T Kisseleva","year":"2008","unstructured":"Kisseleva, T. & Brenner, D. A. Mechanisms of fibrogenesis. Exp. Biol. Med. 233, 109\u2013122 (2008).","journal-title":"Exp. Biol. Med."},{"key":"35212_CR19","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-06-1811","volume":"13","author":"NJ Laping","year":"2007","unstructured":"Laping, N. J. et al. Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats. Clin. Cancer Res. 13, 3087\u20133099 (2007).","journal-title":"Clin. Cancer Res."},{"key":"35212_CR20","doi-asserted-by":"publisher","first-page":"e475","DOI":"10.1002\/ctm2.475","volume":"11","author":"MS Islam","year":"2021","unstructured":"Islam, M. S. et al. Extracellular matrix and Hippo signaling as therapeutic targets of antifibrotic compounds for uterine fibroids. Clin Transl Med 11, e475 (2021).","journal-title":"Clin Transl Med"},{"key":"35212_CR21","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1007\/s11010-021-04174-6","volume":"476","author":"M El Sabeh","year":"2021","unstructured":"El Sabeh, M., Saha, S. K., Afrin, S., Islam, M. S. & Borahay, M. A. Wnt\/\u03b2-catenin signaling pathway in uterine leiomyoma: Role in tumor biology and targeting opportunities. Mol. Cell. Biochem. 476, 3513\u20133536 (2021).","journal-title":"Mol. Cell. Biochem."},{"key":"35212_CR22","doi-asserted-by":"publisher","first-page":"17053","DOI":"10.1073\/pnas.1313650110","volume":"110","author":"M Ono","year":"2013","unstructured":"Ono, M. et al. Paracrine activation of WNT\/\u03b2-catenin pathway in uterine leiomyoma stem cells promotes tumor growth. Proc. Natl. Acad. Sci. U. S. A. 110, 17053\u201317058 (2013).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"35212_CR23","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.fertnstert.2009.08.065","volume":"94","author":"D Zhang","year":"2010","unstructured":"Zhang, D. et al. Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells. Fertil. Steril. 94, 1887\u20131893 (2010).","journal-title":"Fertil. Steril."},{"key":"35212_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000363410","volume":"78","author":"D Zhang","year":"2014","unstructured":"Zhang, D., Rajaratnam, V., Al-Hendy, O., Halder, S. & Al-Hendy, A. Green tea extract inhibition of human leiomyoma cell proliferation is mediated via catechol-o-methyltransferase. Gynecol. Obstet. Invest. 78, 109\u2013118 (2014).","journal-title":"Gynecol. Obstet. Invest."},{"key":"35212_CR25","doi-asserted-by":"publisher","first-page":"289.e281","DOI":"10.1016\/j.ajog.2009.10.885","volume":"202","author":"D Zhang","year":"2010","unstructured":"Zhang, D. et al. Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am. J. Obstet. Gynecol. 202, 289.e281-289.e289 (2010).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"35212_CR26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.nutres.2007.11.009","volume":"28","author":"IH Ozercan","year":"2008","unstructured":"Ozercan, I. H. et al. Chemoprevention of fibroid tumors by [-]-epigallocatechin-3-gallate in quail. Nutr. Res. 28, 92\u201397 (2008).","journal-title":"Nutr. Res."},{"key":"35212_CR27","first-page":"477","volume":"5","author":"E Roshdy","year":"2013","unstructured":"Roshdy, E. et al. Treatment of symptomatic uterine fibroids with green tea extract: A pilot randomized controlled clinical study. Int. J. Womens Health 5, 477\u2013486 (2013).","journal-title":"Int. J. Womens Health"},{"key":"35212_CR28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/nu15020320","volume":"15","author":"H Siblini","year":"2023","unstructured":"Siblini, H. et al. Assessing the hepatic safety of epigallocatechin gallate (EGCG) in reproductive-aged women. Nutrients 15, 320 (2023).","journal-title":"Nutrients"},{"key":"35212_CR29","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/S0015-0282(00)00418-0","volume":"73","author":"A Arici","year":"2000","unstructured":"Arici, A. & Sozen, I. Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil. Steril. 73, 1006\u20131011 (2000).","journal-title":"Fertil. Steril."},{"key":"35212_CR30","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.bbadis.2016.11.006","volume":"1863","author":"AV Shinde","year":"2017","unstructured":"Shinde, A. V., Humeres, C. & Frangogiannis, N. G. The role of \u03b1-smooth muscle actin in fibroblast-mediated matrix contraction and remodeling. Biochim. Biophys. Acta: Mol. Basis Dis. 1863, 298\u2013309 (2017).","journal-title":"Biochim. Biophys. Acta: Mol. Basis Dis."},{"key":"35212_CR31","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.ajpath.2012.02.004","volume":"180","author":"B Hinz","year":"2012","unstructured":"Hinz, B. et al. Recent developments in myofibroblast biology: Paradigms for connective tissue remodeling. Am. J. Pathol. 180, 1340\u20131355 (2012).","journal-title":"Am. J. Pathol."},{"key":"35212_CR32","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1083\/jcb.200704042","volume":"179","author":"P-J Wipff","year":"2007","unstructured":"Wipff, P.-J., Rifkin, D. B., Meister, J.-J. & Hinz, B. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J. Cell Biol. 179, 1311\u20131323 (2007).","journal-title":"J. Cell Biol."},{"key":"35212_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/ndt\/gfh653","volume":"20","author":"J Gaedeke","year":"2005","unstructured":"Gaedeke, J., Boehler, T., Budde, K., Neumayer, H.-H. & Peters, H. Glomerular activin A overexpression is linked to fibrosis in anti-Thy1 glomerulonephritis. Nephrol. Dial. Transplant. 20, 319\u2013328 (2005).","journal-title":"Nephrol. Dial. Transplant."},{"key":"35212_CR34","doi-asserted-by":"publisher","first-page":"e0148969","DOI":"10.1371\/journal.pone.0148969","volume":"11","author":"K Omori","year":"2016","unstructured":"Omori, K. et al. Inhibition of plasminogen activator inhibitor-1 attenuates transforming growth factor-\u03b2-dependent epithelial mesenchymal transition and differentiation of fibroblasts to myofibroblasts. PLoS ONE 11, e0148969 (2016).","journal-title":"PLoS ONE"},{"key":"35212_CR35","first-page":"1","volume":"8","author":"C-C Tsai","year":"2018","unstructured":"Tsai, C.-C., Wu, S.-B., Kau, H.-C. & Wei, Y.-H. Essential role of connective tissue growth factor (CTGF) in transforming growth factor-\u03b21 (TGF-\u03b21)-induced myofibroblast transdifferentiation from Graves\u2019 orbital fibroblasts. Sci. Rep. 8, 1\u201310 (2018).","journal-title":"Sci. Rep."},{"key":"35212_CR36","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.2353\/ajpath.2007.070112","volume":"170","author":"B Hinz","year":"2007","unstructured":"Hinz, B. et al. The myofibroblast: One function, multiple origins. Am. J. Pathol. 170, 1807\u20131816 (2007).","journal-title":"Am. J. Pathol."},{"key":"35212_CR37","doi-asserted-by":"publisher","first-page":"105635","DOI":"10.1016\/j.phrs.2021.105635","volume":"169","author":"M Sun","year":"2021","unstructured":"Sun, M. et al. New insights into the Hippo\/YAP pathway in idiopathic pulmonary fibrosis. Pharmacol. Res. 169, 105635 (2021).","journal-title":"Pharmacol. Res."},{"key":"35212_CR38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrneph.2016.48","volume":"12","author":"X-M Meng","year":"2016","unstructured":"Meng, X.-M., Nikolic-Paterson, D. J. & Lan, H. Y. TGF-\u03b2: The master regulator of fibrosis. Nat. Rev. Nephrol. 12, 325\u2013338 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"35212_CR39","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/j.fertnstert.2019.07.1003","volume":"112","author":"MS Islam","year":"2019","unstructured":"Islam, M. S., Maher, J. Y., Afrin, S., Su, S.-C. & Segars, J. Verteporfin inhibits fibrosis, inflammation and angiogenesis related genes in uterine fibroid cells. Fertil. Steril. 112, e349 (2019).","journal-title":"Fertil. Steril."},{"key":"35212_CR40","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2007.07.019","volume":"130","author":"J Dong","year":"2007","unstructured":"Dong, J. et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130, 1120\u20131133 (2007).","journal-title":"Cell"},{"key":"35212_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-016-0326-1","volume":"16","author":"H Garg","year":"2016","unstructured":"Garg, H., Suri, P., Gupta, J. C., Talwar, G. & Dubey, S. Survivin: A unique target for tumor therapy. Cancer Cell Int. 16, 1\u201314 (2016).","journal-title":"Cancer Cell Int."},{"key":"35212_CR42","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3892\/ijo.2015.3052","volume":"47","author":"H-F Zhao","year":"2015","unstructured":"Zhao, H.-F., Wang, J. & Tony To, S.-S. The phosphatidylinositol 3-kinase\/Akt and c-Jun N-terminal kinase signaling in cancer: Alliance or contradiction?. Int. J. Oncol. 47, 429\u2013436 (2015).","journal-title":"Int. J. Oncol."},{"key":"35212_CR43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00109-002-0408-5","volume":"81","author":"JS Rhim","year":"2003","unstructured":"Rhim, J. S. Generation of immortal human prostate cell lines for the study of prostate cancer. Methods Mol Med 81, 69\u201377 (2003).","journal-title":"Methods Mol Med"},{"key":"35212_CR44","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1365-2265.2008.03207.x","volume":"69","author":"M Malik","year":"2008","unstructured":"Malik, M., Webb, J. & Catherino, W. H. Retinoic acid treatment of human leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells. Clin. Endocrinol. (Oxf) 69, 462\u2013470 (2008).","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"35212_CR45","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1007\/s43032-021-00573-8","volume":"28","author":"B Singh","year":"2021","unstructured":"Singh, B. et al. A phase I clinical trial to assess safety and tolerability of injectable collagenase in women with symptomatic uterine fibroids. Reprod. Sci. 28, 2699\u20132709 (2021).","journal-title":"Reprod. Sci."},{"key":"35212_CR46","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.fertnstert.2009.01.081","volume":"93","author":"DS Joseph","year":"2010","unstructured":"Joseph, D. S., Malik, M., Nurudeen, S. & Catherino, W. H. Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3. Fertil. Steril. 93, 1500\u20131508 (2010).","journal-title":"Fertil. Steril."},{"key":"35212_CR47","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1177\/1933719114545240","volume":"21","author":"M Malik","year":"2014","unstructured":"Malik, M., Britten, J., Segars, J. & Catherino, W. H. Leiomyoma cells in 3-dimensional cultures demonstrate an attenuated response to fasudil, a rho-kinase inhibitor, when compared to 2-dimensional cultures. Reprod. Sci. 21, 1126\u20131138 (2014).","journal-title":"Reprod. Sci."},{"key":"35212_CR48","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.fertnstert.2018.07.024","volume":"110","author":"M Malik","year":"2018","unstructured":"Malik, M., Britten, J., Borahay, M., Segars, J. & Catherino, W. H. Simvastatin, at clinically relevant concentrations, affects human uterine leiomyoma growth and extracellular matrix production. Fertil. Steril. 110, 1398-1407.e1391 (2018).","journal-title":"Fertil. Steril."},{"key":"35212_CR49","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.fertnstert.2020.12.011","volume":"116","author":"CNC Mitchell","year":"2021","unstructured":"Mitchell, C. N. C. et al. Mechanical stiffness augments ligand-dependent progesterone receptor B activation via MEK 1\/2 and Rho\/ROCK\u2013dependent signaling pathways in uterine fibroid cells. Fertil. Steril. 116, 255\u2013265 (2021).","journal-title":"Fertil. Steril."},{"key":"35212_CR50","first-page":"299","volume":"3","author":"D Wright","year":"2022","unstructured":"Wright, D., Britten, J., Malik, M. & Catherino, W. H. Relugolix and elagolix directly inhibit leiomyoma extracellular matrix production in 2-dimesnional and 3-dimensional cell cultures. F S Sci. 3, 299\u2013308 (2022).","journal-title":"F S Sci."},{"key":"35212_CR51","first-page":"74","volume":"4","author":"M Malik","year":"2022","unstructured":"Malik, M. et al. Curcumin inhibits human leiomyoma xenograft tumor growth and induces dissolution of the extracellular matrix. F S Sci. 4, 74\u201389 (2022).","journal-title":"F S Sci."},{"key":"35212_CR52","doi-asserted-by":"publisher","first-page":"105856","DOI":"10.1016\/j.phrs.2021.105856","volume":"172","author":"S Afrin","year":"2021","unstructured":"Afrin, S. et al. Simvastatin modulates estrogen signaling in uterine leiomyoma via regulating receptor palmitoylation, trafficking and degradation. Pharmacol. Res. 172, 105856 (2021).","journal-title":"Pharmacol. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35212-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35212-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35212-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T09:09:16Z","timestamp":1685005756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35212-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["35212"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-35212-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"23 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.H.S. is or was a PI on research sponsored by Bayer, Abbvie, Biospecifics, Allergan, Inc., and Myovant. M.S.I. has nothing to disclose. M.P. has nothing to disclose. J.T.B. has nothing to disclose. B.L.W. has nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8492"}}